
Deciphera Pharmaceuticals DCPH
Annual report 2023
added 02-07-2024
Deciphera Pharmaceuticals Gross Profit 2011-2025 | DCPH
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Quarterly Gross Profit Deciphera Pharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | 19.4 M | 15.4 M | 7.08 M | 62 K | - | - | 25 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 25 M | 62 K | 13.4 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
-40.6 M | $ 4.79 | 2.57 % | $ 795 M | ||
|
Aclaris Therapeutics
ACRS
|
172 K | $ 3.39 | 1.02 % | $ 262 M | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
1.12 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | ||
|
Ascendis Pharma A/S
ASND
|
319 M | $ 213.61 | 1.64 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
90 K | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
-104 K | $ 1.32 | -0.75 % | $ 7.2 M | ||
|
Alterity Therapeutics Limited
ATHE
|
177 K | $ 3.39 | -0.88 % | $ 8.16 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
43.9 B | $ 89.7 | -0.64 % | $ 96.9 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
374 M | $ 25.67 | -0.87 % | $ 1.24 B | ||
|
Anika Therapeutics
ANIK
|
103 M | $ 9.55 | 0.63 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
1.82 K | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
3.22 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
500 | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
53.8 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
45.8 M | $ 2.33 | 2.19 % | $ 14.6 M | ||
|
Arena Pharmaceuticals
ARNA
|
319 K | - | -6.81 % | $ 3.04 B | ||
|
Baudax Bio
BXRX
|
-1.24 M | - | 0.59 % | $ 63 K | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
61.6 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
1.24 B | $ 573.02 | -1.38 % | $ 43.4 B | ||
|
Checkpoint Therapeutics
CKPT
|
1.07 | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
4.15 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
123 M | - | -7.23 % | $ 13 M | ||
|
Biogen
BIIB
|
12.4 B | $ 174.8 | 1.33 % | $ 25.5 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
371 M | $ 11.54 | 0.87 % | $ 746 M | ||
|
Benitec Biopharma
BNTC
|
282 K | $ 12.57 | -3.01 % | $ 517 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
200 K | - | -5.68 % | $ 8.28 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.03 M | $ 0.29 | -1.45 % | $ 631 M | ||
|
Catalyst Biosciences
CBIO
|
109 M | $ 15.4 | 0.59 % | $ 1.01 B | ||
|
Enochian Biosciences
ENOB
|
37.5 K | - | - | $ 40.5 M | ||
|
Epizyme
EPZM
|
10.7 M | - | - | $ 249 M | ||
|
Cerus Corporation
CERS
|
60.4 M | $ 2.22 | 3.02 % | $ 410 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K |